Business Context and Reporting Period
Harmony Biosciences Holdings, Inc. filed this Form 8-K under Item 5.07 regarding its 2023 Annual Meeting of Stockholders held on May 25, 2023. The report was signed and filed on May 26, 2023.
Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating and financial metrics.
Material Changes
- Antonio Gracias, Jack Bech Nielsen, and Andreas Wicki, Ph.D. were elected as Class II directors to serve until the 2026 annual meeting and until their successors are elected and qualified.
- Stockholders ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
- Stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance, outlook, management commentary, risk updates, contingencies, or unusual financial items.
Key Facts to Verify
- Director election results: Gracias received 41,295,494 votes for, Nielsen received 38,571,010, and Wicki received 37,229,122.
- Deloitte & Touche LLP ratification results: 53,633,333 votes for, 25,629 against, and 8,596 abstentions.
- Advisory executive compensation results: 51,543,958 votes for, 1,252,960 against, 406,969 abstentions, and 463,671 broker non-votes.